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Abstract  
Objectives: The impact of response to first-line tyrosine kinase inhibitor (TKI) 
therapy on second-line survival in patients with metastatic renal cell carcinoma 
(mRCC) who receive second-line molecular-targeted therapy (mTT) after first-
line failure remains unclear. 
Materials and methods: Sixty patients who developed disease progression after 
first-line TKI, without prior cytokine therapy, were enrolled. According to the 
median first-line time to progression (1L-TTP), patients were divided into two 
groups (i.e., short vs. long). Second-line progression-free survival (2L-PFS) and 
second-line overall survival (2L-OS) were defined as the time from second-line 
mTT initiation. Survival was calculated with the Kaplan-Meier method and 
compared using the log-rank test between patients with short and long 1L-PFS.  
Predictors for survivals were identified using Cox proportional hazards regression 
models.  
Results: The median 1L-TTP was 8.84 months. Thirty patients (50.0%) with short 
1L-TTP (<8.84 months) had significantly shorter 2L-PFS and 2L-OS compared to 
patients with long 1L-TTP (2L-PFS: 4.96 vs. 10.2 months, p = 0.0002; 2L-OS: 9.6 
vs. 28.0 months, p = 0.0036). Multivariable analyses for 2L-PFS and 2L-OS 
4 
 
showed that 1L-TTP was an independent predictor both as a categorical 
classification (cutoff: 8.84 months) and as a continuous variable (both p <0.05). 
The median follow-up duration was 13.1 months (interquartile range: 6.56 – 24.7). 
Conclusions: Patients who achieve a long-term response after first-line TKI 
therapy could have a favorable prognosis with second-line mTT. 
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1. Introduction  
Molecular-targeted therapy (mTT) contributed to the improvement in prognosis 
for patients with metastatic renal cell carcinoma (mRCC) compared to earlier 
treatments with cytokine therapy [1]. After failure of first-line therapy, subsequent 
second-line therapy is performed to prolong overall survival (OS) [2]. According 
to a previous study, just 100 of 2803 patients (3.57%) achieved a complete 
response after first-line therapy [3]; most patients had subsequent disease 
progression even after mTT initiation. Therefore, effective prognosis prediction 
after sequential mTT is important, and numerous studies have been performed 
to evaluate and establish a more effective and safe treatment strategy. For 
example, the Memorial Sloan Kettering Cancer Center (MSKCC) and the 
International Metastatic Renal-Cell Carcinoma Database Consortium risk 
classifications include well-known predictors for first- and second-line therapies 
[4-7]. Imaging evaluations, including the magnitude of early or best tumor 
shrinkage, and tumor burden have also been identified as useful factors [8-12]. 
Additionally, systematic inflammatory markers including C-reactive protein or 
sarcopenia have been recently highlighted as significant predictors for patients 
with mRCC [13, 14]. In this context, several studies have investigated whether 
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the response to first-line therapy, such as time to progression (TTP), could predict 
second-line outcome in sequential mTT. However, to date, the correlation 
between first- and second-line survival remains controversial [2, 15-18]. 
Thus, in the present study, we evaluated the influence of TTP during first-line 
tyrosine kinase inhibitor (TKI) therapy on survival after second-line therapy in a 
cohort of patients with mRCC after first-line failure without prior cytokine therapy.  
 
2. Patients and methods 
 Between January 2007 and March 2016, a total of 123 patients at our 
department received second-line mTT for mRCC. Several patients were excluded 
because they received prior cytokine therapy (n = 29), first-line mammalian target 
of rapamycin inhibitor (mTORi) therapy (n = 11), or underwent hemodialysis or 
kidney transplant (n = 4). Eleven patients whose reason for shifting second-line 
therapy was adverse events during first-line therapy were excluded. After 
exclusion of 8 patients whose data were missing, the remaining 60 patients were 
enrolled in this analysis (Figure 1).  
All study procedures were approved by the Institutional Review Board of Tokyo 
Women’s Medical University (ID: 3824), and were in accordance with the 
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Declaration of Helsinki.  
 
2.1 Study design and endpoint 
 The endpoints of this study were progression-free survival (PFS) and OS after 
second-line mTT initiation (2L-PFS and 2L-OS). First-line TTP (1L-TTP) was 
defined as the time from first-line mTT initiation to the date of progression. We 
divided patients into two groups based on the median duration of 1L-TTP (i.e., 
long vs. short). In this study, the median 1L-TTP was 8.84 months (interquartile 
range 5.3 – 14.0 months). Based on this cut-off value, patients were divided into 
two groups, as follows: 30 patients (50.0%) with short 1L-TTP (<8.84 months) 
and 30 patients (50.0%) with long 1L-TTP (≥8.84 months). Clinicopathological 
parameters, including sex, age at the time of second-line initiation, pathology, 
first- and second-line MSKCC risk, the number and sites of organs involved by 
metastatic disease at the time of second-line initiation, first- and second-line 
agent, and follow-up duration were compared between patients with long and 
short 1L-TTP. Second-line MSKCC risk was defined according to Motzer’s risk 
classification [6]. Moreover, adverse events (AEs) that required dose modification, 
including reduction and discontinuation, and reasons for second-line therapy 
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discontinuation were compared. AEs were graded using the Common 
Terminology Criteria for Adverse Events of the National Cancer Institute, version 
4.0. 2L-PFS and 2L-OS were also compared according to 1L-TTP, and predictors 
of 2L-PFS and 2L-OS were analyzed by multivariable analyses using factors that 
could be evaluated at the time of second-line initiation.  
 
2.2 Protocols of molecular-targeted therapies 
 Our protocols for mTT have been described previously [10, 19].  
A main agent for first-line TKI therapy is sunitinib. In the sunitinib regimen, we 
recently used a 2-week-on/1-week-off schedule, based on findings from our 
previous study [19]. Sunitinib treatment was orally initiated at a dosage of 50 
mg/day and was modified according to patients’ conditions. When patients had a 
poor performance status or were elderly (>80 years), sorafenib or pazopanib is 
chosen. In the sorafenib regimen, 200 mg sorafenib was orally administered twice 
daily and was increased up to 800 mg within 2-4 weeks to reduce the acute 
dermatological reaction, with a continuous dosing schedule. In the pazopanib 
regimen, pazopanib was orally administered once daily at a dose of 800 mg, with 
continuous dosing. The dose was reduced to 600 mg and then to 400 mg 
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according to the severity of AEs. In Japan, first -line axitinib therapy was not 
covered by insurance; we used axitinib administration as second- and 
subsequent therapy. In the axitinib regimen, patients received 5 mg of axitinib 
orally twice daily with a continuous dosing schedule. Based on patients’ 
tolerability, the dosage of axitinib could either increase to 7 mg twice daily or it 
could be reduced to 3 mg twice daily and then further to 2 mg twice daily, if needed. 
Patients received oral everolimus 10 mg once daily until disease progression or 
unacceptable toxicity. A dose reduction to 5 mg once daily was permitted. 
Temsirolimus was administered weekly at a fixed dose of 25 mg intravenously.  
 
2.3 Statistical analysis 
Continuous variables were analyzed using the Mann-Whitney U-test, and 
categorical variables were analyzed using the χ2 test. PFS was defined as the 
time from therapy initiation to the date of progression or death from any cause, 
whichever came first. OS was defined as the time from therapy initiation to death 
from any cause. Survival was calculated with the Kaplan-Meier method and 
compared using the log-rank test between patients with long vs. short 1L-TTP. 
Univariable and multivariable analyses using Cox proportional hazards 
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regression models were used to identify predictors of survival. To manage larger 
statistical effects for categorical classification based on dichotomous values in 
1L-TTP, we performed multivariable analyses using both a categorical 
classification (Model 1) and a continuous variable (Model 2). Survival risk was 
expressed as hazard ratios (HR) and 95% confidence intervals (CIs). All analyses 
were performed using JMP software (version 11; SAS Institute Inc., Cary, NC, 
USA), and p-values <0.05 were considered statistically significant. 
 
3. Results 
3.1 Patient and tumor characteristics  
Among the patient characteristics, including sex, age, first- and second-line 
MSKCC risks, and agents, only first-line MSKCC risk was significantly poorer in 
patients with short 1L-TTP (p = 0.0288). With respect to the tumor characteristics, 
including pathology, number of organs with metastasis disease, and metastatic 
sites (i.e., lymph nodes, lung, bone and liver), there were no significant 
differences (all p >0.05). Neither AEs that required dose modification nor reasons 
for second-line therapy discontinuation significantly differed between groups 
(both p >0.05). Follow-up duration was significantly shorter in patients with short 
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1L-TTP (p = 0.0008) (Table 1). 
 
3.2 Survival according to 1L-TTP 
During the follow-up period, disease progression and death due to any cause 
occurred in 49 (81.7%) and 41 (68.3%) patients, respectively. As shown in 
Figures 2a and 2b, 2L-PFS and 2L-OS were significantly shorter in patients with 
short 1L-TTP compared to those with long 1L-TTP (2L-PFS: 4.96 vs. 10.2 
months; p = 0.0002; 2L-OS: 9.6 vs. 28.0 months; p = 0.0036).  
 
3.3 Survival according to 1L-TTP and second-line agent 
To evaluate the influence of second-line targeted agent, we divided patients into 
4 subgroups according to the combination of 1L-TTP and second-line agent: 
patients with long 1L-TTP and second-line mTORi (n = 7), long 1L-TTP and 
second-line TKI (n = 23), short 1L-TTP and second-line mTORi (n = 5), and short 
1L-TTP and second-line TKI (n = 25). There were no significant differences in 2L-
PFS and 2L-OS in terms of 1L-TTP and type of second-line agent (all p > 0.05) 
(Figures 3a and 3b). 
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3.4 Predictors for 2L-PFS and 2L-OS 
As shown in Table 2, univariable analysis for 2L-PFS showed that pathology, 
second-line MSKCC risk, the number of organs with metastatic disease, and 1L-
TTP were significant factors. Multivariable analysis for 2L-PFS showed that 1L-
TTP was an independent predictor both as a categorical classification (Model 1: 
HR 2.45, p = 0.0097) and as a continuous variable (Model 2: HR 0.95, p = 0.0034). 
Pathology in Model 1, and the number of organs with metastatic disease in 
Models 1 and 2, were also independent factors for 2L-PFS (all p<0.05).  
As shown in Table 3, the univariable analysis for 2L-OS showed that pathology, 
second-line MSKCC, the number of organs with metastatic disease, presence of 
lymph node and lung metastases, and 1L-TTP were significant factors. The 
multivariable analysis for 2L-OS showed that 1L-TTP was an independent 
predictor both as a categorical classification (Model 1: HR 2.37, p = 0.176) and 
as a continuous variable (Model 2: HR 0.95, p = 0.0106). Both in Models 1 and 
2, second-line MSKCC risk, the number of organs with metastatic disease, and 
the presence of lymph node metastasis were also independent factors for 2L-OS 
(all p>0.05).  
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4. Discussion  
The influence of clinical response to first-line TKI on outcome after sequential 
second-line therapy has been discussed. Al-Marrawi et al. indicated that there 
were no correlations between first- and second-line PFS in a cohort of 464 
patients who received TKI-TKI therapy for mRCC [18]. Similarly, Miyazaki et al. 
suggested that no significant correlation of PFS was identified in 76 patients 
receiving TKI-TKI [17]. Meanwhile, a sub-analysis of the AXIS trial, the first 
randomized phase III trial study to compare two active TKI agents, axitinib vs. 
sorafenib, for second-line treatment of mRCC [20, 21], showed that longer prior 
treatment with sunitinib or cytokines was generally associated with longer OS 
with second-line axitinib or sorafenib [15]. Another retrospective study of 119 
patients with mRCC showed that PFS > 6 moths with a prior TKI (sunitinib, 
sorafenib, or axitinib) was a prognostic factor for longer OS with a second-line 
TKI or mTORi [2]. Finally, a recent study of mRCC with clear-cell histology 
reported that 241 patients who remained on first-line TKI between 11 and 22 
months benefited from second-line TKI rather than mTORi [16]. Thus, it has been 
suggested that the short- or long-term response to a first-line TKI therapy should 
guide optimal choice of the second-line agent [22]. In this context, we indicated 
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that longer response to first-line TKI therapy could predict favorable prognosis 
after second-line mTT for mRCC, supporting the findings of previous studies [15, 
16]. Interestingly, we also found that tolerability for second-line therapy (i.e., AEs 
rate and reasons for therapy termination) was not associated with first-line 
response as shown in Table 1; 1L-TTP predicted second-line survival regardless 
of second-line tolerability.  
 In the present cohort, patients with prior cytokine therapy were excluded; this 
represents a unique aspect of this study in comparison to previous analyses [2, 
15, 16]. The current treatment strategy consists of mTT, not cytokines [23, 24]. To 
the best of our knowledge, this was the first study demonstrating a significant 
association between first- and second-line outcomes in sequential mTT without 
prior cytokine therapy. Moreover, as described in a study of Escudier et al., 
patients who had been previously treated with cytokines for a long period without 
disease progression may have had inherently less-aggressive disease or better 
general condition; that is, possible bias exists [15]. Therefore, we believe that our 
finding in this setting provides important information for physicians.  
Unfortunately, we could not identify an indication for second-line therapy (i.e., 
TKI vs. mTORi) due to the small number of patients receiving second-line mTORi, 
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although the selection of second-line agent does not appear to be associated with 
prognosis (Figures 3a and 3b). This finding was consisted with our previous 
report [25]. Several studies have been performed to clarify the superiority of 
sequential second-line therapy. Busch et al. compared TKI-TKI and TKI-mTORi 
groups and suggested that they were equally efficacious in terms of PFS and 
response rate, whereas the TKI-mTORi group had a tendency toward improved 
OS [26]. Meanwhile, in the INTORSECT trial, longer OS, but not PFS, was 
observed in patients with sunitinib-sorafenib vs. sunitinib-temsirolimus treatment 
[27]. Finally, Park et al. reported that second-line TKI seemed to be as effective 
as mTORi after first-line TKI failure in terms of PFS and OS [28]. Thus, there has 
not been strong evidence demonstrating the superiority between second-line TKI 
vs. mTORi, and it is possible that there is no difference in outcome between them. 
In this context, Elaidi et al. indicated that second-line TKI, rather than mTORi, 
was recommended in patients with long response to first-line TKI [16]. This finding 
might also be observed in the present study; as shown in Figure 3a, patients who 
had a long 1L-TTP had longer 2L-PFS after second-line TKI, compared to that 
after second-line mTORi, although this difference was not statistically significant 
(19.4 vs. 7.2 months, p = 0.155). Meanwhile, in OS, there was no superiority 
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between second-line TKI and mTORi; this might be due to equal efficacy in terms 
of OS for third-line therapy of TKI-TKI-mTORi vs. TKI-mTORi-TKI, as previously 
reported [29]. It is difficult to explain the mechanism of these findings; the 
response to mTT may depend on not only the power of the targeted agents in 
terms of tumor shrinkage or suppression, but also tumor characteristics such as 
sensitivity to therapy or inherent tumor aggressiveness.  
The present study has several limitations. First, this study was retrospectively 
performed in a single-center with a small cohort; therefore, unavoidable biases in 
patient selection or findings obtained from the analyses exist. Secondly, regimens 
of mTT were heterogeneous, also potentially introducing bias. Third, dose-limiting 
toxicity or relative dose intensity in each agent was not evaluated. Therefore, the 
findings of the present study should be confirmed in a further analysis with a large 
and homogeneous cohort in terms of patients’ characteristics and mTT regimens. 
 
5. Conclusions  
This study revealed that long 1L-TTP with first-line TKI therapy was associated 
with long 2L-PFS and 2L-OS after second-line mTT in a cohort of mRCC patients 
without prior cytokine therapy. Although the superiority of TKI over mTORi in 
17 
 
second-line therapy could not be confirmed, long response to first-line therapy is 
a useful factor for the prediction of favorable outcome after second-line mTT, 
regardless of second-line agent. This information is useful for physicians to 
establish the treatment strategy for second-line therapy after first-line TKI failure.    
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Figure legends  
Figure 1: Patient selection 
 
Figure 2: Second-line progression-free and overall survivals according to first-line 
time to progression  
(a, b) A short first-line time to progression was significantly associated with 
shorter second-line progression-free and overall survivals compared to that for a 
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long first-line time to progression (median second-line progression-free survival: 
4.96 vs. 10.2 months; median overall survival: 9.6 vs. 28.0 months) 
TTP, time to progression  
 
Figure 3: Second-line progression-free and overall survivals according to first-line 
time to progression and second-line agents 
(a, b) There were no significant differences in second-line progression-free or 
overall survival between second-line agents, regardless of first-line time to 
progression. 
*Performed between mTORi vs. TKI in patients with long 1L-TTP 
** Performed between mTORi vs. TKI in patients with short 1L-TTP 
mTORi, mammalian target of rapamycin inhibitor; TKI, tyrosine kinase inhibitor 
Table 1: Patient and tumor characteristics  
Parameter Short 1L-TTP 
(n = 30) 
Long 1L-TTP 
(n = 30) 
p 
Sex, % 
 Male (ref. female) 
 
19 (63.3) 
 
23 (76.7) 
0.260 
Age, % 
 ≥65 years (ref. < 65) 
 
16 (53.3) 
 
19 (63.3) 
0.432 
Pathology, % 
 Clear-cell carcinoma 
 Non-clear-cell carcinoma 
  Papillary renal cell carcinoma type 2 
  Clear-cell carcinoma with spindle cell 
  Others/ Unknown   
 
20 (66.7) 
10 (33.3)  
4 (13.3) 
3 (10.0) 
3 (10.0) 
 
26 (86.7) 
4 (13.3) 
1 (3.33) 
1 (3.33) 
2 (6.66) 
0.0670 
MSKCC risk, % 
 Favorable/intermediate/poor 
 
1 (3.33)/24 (80.0)/5 (16.7) 
 
8 (26.7)/20 (66.7)/2 (6.67) 
0.0288 
Second-line MSKCC risk, % 
 Favorable/intermediate/poor 
 
2 (6.67)/16 (53.3)/12 (40.0) 
 
3 (10.0)/23 (76.7)/4 (13.3) 
0.0653 
Number of organs with metastatic disease, %  
 Multiple (ref. solitary) 
 
21 (70.0) 
 
21 (70.0) 
1.000 
Lymph node metastasis, %  
 With (ref. without) 
 
10 (33.3) 
 
9 (30.0%) 
0.781 
Lung metastasis, %  
 With (ref. without) 
 
24 (80.0) 
 
26 (86.7%) 
0.488 
Bone metastasis, %  
 With (ref. without) 
 
3 (10.0) 
 
9 (30.0%) 
0.0528 
Liver metastasis, %  
 With (Without) 
 
6 (20.0) 
 
4 (13.3%) 
0.488 
First-line agent, %  
 TKI 
  Sorafenib/Sunitinib/Pazopanib 
 
30 (100) 
10 (33.3)/19 (63.3)/1 (3.33) 
 
30 (100) 
11 (36.7)/ 18 (60.0)/1 (3.33) 
0.963 
Second-line agent, % 
 TKI 
  Sorafenib/Sunitinib/Axitinib/Pazopanib 
 mTORi 
  Temsirolimus/Everolimus 
 
25 (83.3) 
1 (3.33)/7 (23.3)/16 (53.3)/1 (3.33) 
5 (16.7) 
2 (6.67)/3 (10.0) 
 
23 (76.7) 
1 (3.33)/6 (20.0)/14 (46.7)/2 (6.67) 
7 (23.3) 
2 (6.67)/5 (16.7) 
0.519 
Adverse events requiring dose modification, % 
 Any grade  
  With (ref. without) 
 Grade 2  
  With (ref. without) 
Grade 3 or more 
 With (ref. without)  
 
 
23 (76.7) 
 
11 (36.7) 
 
13 (43.3) 
 
 
21 (70.0) 
 
11 (36.7) 
 
11 (36.7%) 
 
0.559 
 
1.00 
 
0.598 
*Reasons for second-line therapy discontinuation, % 
 Disease progression 
 Adverse events 
 Others 
 
27 (93.1) 
0 
2 (6.90) 
 
20 (76.9) 
3 (11.5) 
3 (11.5) 
0.129 
**Follow-up, months 7.87 (4.84 – 17.5) 21.7 (11.1 – 28.3) 0.0008 
*Evaluated in 55 patients (short 1L-TTP: 29; long 1L-TTP: 36 patients) after excluding 5 patients who were still ongoing when these analyses were 
performed. 
**Median and interquartile range 
 
Clinicopathological characteristics of 60 patients with metastatic renal cell carcinoma who underwent second line molecular- targeted therapy after 
first-line tyrosine kinase inhibitor failure 
 
TTP, time to progression; MSKCC, Memorial Sloan Kettering Cancer Center; TKI, tyrosine kinase inhibitor; mTORi, mammalian target of rapamycin 
inhibitor  
 
 
 
 
 
 
 
Table 2: Results of univariable and multivariable analyses for 2L-PFS 
Parameter  Univariate 
OR (95%CI) 
p Model 1 
Multivariate 
OR (95%CI) 
p Model 2 
Multivariate  
OR (95%CI) 
p 
Sex 
 Male (ref. female) 
 
0.65 (0.36 – 1.20) 
0.164 
    
Age, years 
 ≥ 65 (ref. < 65) 
 
0.77 (0.44 – 1.38) 
0.377 
    
Pathology 
 Clear-cell carcinoma (ref. non-clear-cell 
carcinoma) 
 
0.40 (0.21 – 0.80) 
0.0107  
0.45 (0.23 – 0.93) 
0.0330  
0.51 (0.26 – 1.06) 
0.0686 
MSKCC risk 
 Poor (ref. favorable/intermediate) 
 
0.99 (0.34 – 2.30) 
0.988 
    
Second-line MSKCC risk 
 Poor (ref. favorable/intermediate) 
 
3.02 (1.54 – 5.68) 
0.0017  
1.75 (0.84 – 3.56) 
0.133  
2.08 (1.02 – 4.11) 
0.0448 
Number of organs with metastatic disease 
 Multiple (ref. solitary) 
 
1.93 (1.02 – 3.91) 
0.0426  
2.09 (1.09 – 4.30) 
0.0265  
2.06 (1.07 – 4.25) 
0.0309 
Lymph node metastasis  
 With (ref. without) 
 
1.42 (0.75 – 2.57) 
0.274     
Lung metastasis  
 With (ref. without) 
 
0.55 (0.28 – 1.18) 
0.118     
Bone metastasis  
 With (ref. without) 
 
0.82 (0.37 – 1.63) 
0.597     
Liver metastasis  
 With (Without) 
 
1.32 (0.54 – 2.79) 
0.511     
First-line agent 
 Sutinitinb/pazopanib (ref. sorafenib) 
 
1.18 (0.65 – 2.29) 
0.592 
    
Second-line agent 
 TKI (ref. mTORi) 
 
0.65 (0.35 – 1.32) 
0.225 
    
1L-TTP, month (categorical classification)  
 <8.84 (ref. ≥ 8.84) 
 
2.95 (1.62 – 5.45) 
0.0004  
2.45 (1.24 – 4.82) 
0.0097 - - 
1L-TTP, month (continuous variable) 0.94 (0.90 – 0.97) 0.0003 - - 0.95 (0.91 – 0.98) 0.0034 
OR, odds ratio; CI, confidence interval 
Model 1: A model with 1L-TTP as a categorical classification  
Model 2: A model with 1L-TTP as a continuous variable 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Results of univariable and multivariable analyses for 2L-OS 
Parameter  Univariate 
OR (95%CI) 
p Model 1 
Multivariate 
OR (95%CI) 
p Model 2 
Multivariate  
OR (95%CI) 
p 
Sex 
 Male (ref. female) 
 
0.69 (0.37 – 1.33) 
0.261 
    
Age, years 
 ≥ 65 (ref. < 65) 
 
0.71 (0.38 – 1.32) 
0.274 
    
Pathology 
 Clear-cell carcinoma (ref. non-clear cell 
carcinoma) 
 
0.41 (0.21 – 0.88) 
0.0230  
0.61 (0.28 – 1.39) 
0.232  
0.64 (0.30 – 1.46) 
0.279 
MSKCC risk 
 Poor (ref. favorable/intermediate) 
 
1.20 (0.35 – 3.07) 
0.742     
Second-line MSKCC risk 
 Poor (ref. favorable/intermediate) 
 
2.96 (1.49 – 5.69) 
0.0027  
2.48 (1.16 – 5.15) 
0.0201  
2.42 (1.14 – 4.98) 
0.0218 
Number of organs with metastatic disease 
 Multiple (ref. solitary) 
 
2.88 (1.37 – 6.86) 
0.0044  
2.40 (1.12 – 5.79) 
0.0239  
2.42 (1.12 – 5.82) 
0.0243 
Lymph node metastasis  
 With (ref. without) 
 
2.01 (1.03 – 3.78) 
0.0410  
2.56 (1.25 – 5.12) 
0.0110  
3.01 (1.46 – 6.07) 
0.0034 
Lung metastasis  
 With (ref. without) 
 
2.50 (1.10 – 5.18) 
0.0307  
2.41 (0.99 – 5.44) 
0.0522  
2.41 (0.99 – 5.45) 
0.0530 
Bone metastasis  
 With (ref. without) 
 
1.11 (0.47 – 2.30) 
0.798     
Liver metastasis  
 With (Without) 
 
1.87 (0.75 – 4.10) 
0.168     
First-line agent 
 Sutinitinb/pazopanib (ref. sorafenib) 
 
1.01 (0.53 – 2.01) 
0.982     
Second-line agent 
 TKI (ref. mTORi) 
 
1.13 (0.56 – 2.50) 
0.735     
1L-TTP, month (categorical classification)  
 <8.84 (ref. ≥8.84) 
 
2.48 (1.32 – 4.73) 
0.0047  
2.37 (1.16 – 4.93) 
0.0176 - - 
1L-TTP, month (continuous variable) 0.95 (0.91 – 0.99) 0.0057 - - 0.95 (0.90 – 0.99) 0.0106 
Model 1: A model with 1L-TTP as a categorical classification  
Model 2: A model with 1L-TTP as a continuous variable 



